| Biomarker ID | 425 |
| PMID | 19229851 |
| Year | 2009 |
| Biomarker | Gleason sum +TGFB1+ IL-6sR +VCAM1+uPA |
| Biomarker Basis | Expression Based |
| Biomolecule | Protein |
| Source | Plasma |
| Subjects | Humans |
| Regulation | Increased Expression with Biochemical Recurrence |
| Odds Ratio/Hazard Ratio/Relative Risk | NA |
| Effect on Pathways | Pathways Include(VCAM1):-Integrin beta-2 pathway, Cells and molecules involved in local acute inflammatory response,TWEAK regulation of gene expression,Alpha-9 beta-1 integrin pathway,RAGE pathway |
| Experiment | Recurrence Vs No recurrence for 5 years |
| Type of Biomarker | Prognostic |
| Cohort | A cohort of 423 men was used to develop and internally validate the post-operative nomogram for prediction of Biochemical Recurrance. |
| Senstivity | NA |
| Specificity | NA |
| AUC | NA |
| Accuracy | Concordance Index = 86.1% |
| Level Of Significance | NA |
| Method Used | enzyme immunoassays |
| Clinical | No |
| Remarks | When the prediction model only consisted of percent-free PSA ,pathologic Gleason, surgical margin status and lymph node, the accuracy was 82.1%. Addition of these biomarkers resulted in an increased c-index accuracy. |
| Clinical Trial Number | NA |
| Degree Of Validity | Not validated on independent patient dataset |
| Technical Name | TGFB1, IL6, VCAM1, uPA |